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The cystic fibrosis transmembrane conductance regulator (CFTR) functions as a cAMP-activated chloride channel, which is regulated by
protein–protein interactions. The extent to which CFTR is regulated by these interactions remains unknown. Annexin V is overexpressed in cystic
fibrosis (CF), and given the functional properties of annexin V and CFTR we considered whether they are associated and if so whether this has
implications for CFTR function. Using co-immunoprecipitation and overlay experiments, we show that annexin V is associated with nucleotide-
binding domain 1 (NBD1) of CFTR. Surface plasmon resonance (SPR) indicated different KD values in the absence and presence of both calcium
and ATP, suggesting that this interaction is calcium- and ATP-dependent. Using an siRNA approach and overexpression, we showed that CFTR
chloride channel function and its localization in the cell membranes were dependent on annexin V expression. We concluded that annexin V is
necessary for normal CFTR chloride channel activity. Furthermore, we show that CFTR and annexin V are partially co-distributed in normal
epithelial cells in human bronchi. In conclusion, we show for the first time that annexin V is associated with CFTR and is involved in its function.
© 2007 Elsevier B.V. All rights reserved.Keywords: Protein–protein interaction; Normal CFTR function; Protein localization1. Introduction
Cystic fibrosis (CF) is a lethal autosomal recessive disease
characterized by defects in epithelial ion transport [1]. CF is
caused by mutations in both CFTR alleles encoding the cystic
fibrosis transmembrane conductance regulator (CFTR) [1,2].
This ATP-binding cassette transporter functions as a chloride
(Cl−) channel [2–4] and comprises two hydrophobic core re-
gions, two nucleotide-binding domains (NBDs) with ATP-
binding activity [5] and a regulatory domain (R domain). CFTR
channel opening requires phosphorylation by cAMP-dependent
protein kinases (PKA, [6]) and hydrolyzable MgATP [7,8].
Since the CFTR gene was cloned in 1989, more than 1300
mutations have been described and, despite being a monogenic
disease, CF appears to be very heterogeneous with a phenotype⁎ Corresponding authors. Tel.: +33 2 98 01 81 47; fax: +33 2 98 01 83 42.
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doi:10.1016/j.bbadis.2007.06.006that ranges from nonclinical to clinical (congenital absence of
vas deferens, mild pulmonary disease and idiopathic chronic
pancreatitis). The severity of CF phenotype is influenced by
other factors including gene modifiers and interactions between
CFTR and its partners. Although several attempts have been
made to correlate phenotype and genotype among patients
sharing the same mutations, this correlation remains elusive and
both genetic and environmental factors seem to be involved.
CFTR regulation is complex and involves dimerization of the
protein [9,10] and interdomain interactions [11]. Syntaxin 1A,
EBP50, E3KARP, the μ subunit of the endocytic clathrin adaptor
complex and cysteine string proteins are CFTR-binding proteins
[12–15,2], but the extent to which CFTR channels are regulated
by protein–protein interactions remains largely unknown.
Our aim was to identify new wild-type CFTR-binding pro-
teins to improve our understanding of the pathophysiology of
CF. We focused on annexin V which is overexpressed in CF
epithelial cells from foetal trachea [16]. Although the exact role
of annexin V in cells is unknown, it has been shown to bind to
phosphatidylserine (PS) in the presence of calcium [17–19].
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indicating that the two proteins may have the same cellular
location. We therefore hypothesized that annexin V and CFTR
may be co-distributed in cells and maybe interact. We also
hypothesized that there is a possible functional link between the
two proteins, since annexin V was recently shown to interact
with membrane proteins and to regulate the sodium–calcium
exchanger and caveolin in cardiomyocytes [21].
Using co-immunoprecipitation, overlay experiments and
surface plasmon resonance (SPR), we show that annexin V
and CFTR interact directly. Furthermore, we show that this
interaction involves the NBD1 domain of CFTR. In addition,
this interaction is reinforced in the presence of both calcium ions
and MgATP, as shown by Scatchard analysis of the dissociation
constants (KD) of the interaction in the absence and presence of
calcium and ATP. The chloride channel function of CFTR was
studied in A549 cells in the presence of siRNA directed against
annexin V and when annexin V was overexpressed. Functional
experiments (SPQ) showed that the decreased expression of
annexin V was correlated with a decreased CFTR chloride
channel function due to a decreased CFTR accumulation in the
cell membranes. Conversely, overexpression of annexin V in-
creased CFTR function and membrane localization. Therefore,
we have shown for the first time that annexin V interacts directly
with CFTR and that normal CFTR chloride function requires the
presence of annexin V in cells. Confocal microscopy showed
that annexin V and CFTR are partially co-distributed in human
bronchial cells, indicating the physiological relevance of our
findings.
2. Methods
2.1. Protein extraction and co-immunoprecipitation
Normal human tissues from the upper airways (nasal tissues) were obtained
from the Hôpital de la Cavale Blanche (Brest, France) following approval by the
local ethics committee. The tissues were homogenized in lysis buffer (50 mM
Tris–HCl, 100 mM NaCl, 1% Triton X-100, 1.1 μM leupeptin, 0.7 μM
aprotinin, 120 μM PMSF, 1 μM iodoacetamide, 0.7 μM pepstatin and 1 mM
DIFP; all from Sigma) using a polytron. Co-immunoprecipitations were carried
out with Dynabeads (Dynal Biotech) coated with monoclonal anti-CFTR
antibodies (10 μg/ml, MM 13-4, RD System). The presence of CFTR protein in
the complex was assessed and compared with a negative control in which the
beads were coated with an irrelevant antibody directed against mouse Ig (not
shown). A second control was performed by incubating the coated beads with
the proteins extracted from untransfected A549 cells, which do not express the
CFTR protein. The role of calcium was also checked by performing similar co-
immunoprecipitation with CaCl2 (10
−5 M), EDTA or EGTA (10−3 M). After
incubation, the beads were extensively washed and the samples were analyzed
by Western blot (12% gel electrophoresis) using a polyclonal anti-annexin V
antibody (1/1000, sc-1929 Invitrogen). Controls were performed without
primary antibody, without secondary antibody (not shown).
2.2. Cell culture and transfection
A549 cells, an alveolar type II epithelium-like cell line provided by the
American Type Culture Collection (Rockville, MD), were cultured in Ham's
F-12 medium (M.E. Kaighn's modified medium) supplemented with 10% foetal
calf serum, 50 mg/ml streptomycin and 50 U/ml penicillin in a 5%CO2-balanced
air incubator at 37 °C.
A549 cells were further transfected using Lipofectamine 2000 (Life
Technologies) according to the manufacturer's instructions, with the full-lengthnormal human CFTR cDNA (Transgene SA, pTG5985, France, access Genbank
no. M28668) inserted in pcDNA3.1 myc-His (Invitrogen) between the KpnI and
XhoI restriction sites, providing a C-terminal HisX6 tail. Stably transfected
clones were isolated by neomycin selection. After 10 passages, the expression of
the CFTR protein was assessed by immunofluorescent labelling and Western
blotting (not shown). DelF508-CFTR expressing cells were also generated.
Mutagenesis was performed on the cDNA encoding the CFTR protein, using the
QuickChange® XL Site-directed Mutagenesis Kit according to the manufac-
turer's instructions (Stratagene, USA). The mutated oligonucleotides (Eurobio,
France) that correspond to the ÄF508 mutation were: 5′-CTGGCACCAT-
TAAAGAAAATATCGGTGTTTCCTATGATG-3′;5′-CATCATAGGAAA-
CACCGATATTTCTTTAATGGTGCCAG-3′. The delF508 mutation was
controlled by double-strand sequencing (ABI 310, Applied Biosystem, USA)
and Western blotting (not shown).
In A549 cells stably expressing CFTR, annexin V was inhibited using an
siRNA specifically designed to knockdown gene expression according to the
manufacturer's instructions (Santa Cruz Biotechnology). siRNA buffer alone,
or an irrelevant scrambled siRNA provided by the manufacturer, was used as
a negative control according to the manufacturer's instructions. According to
the manufacturer (Santa Cruz Biotechnology), the scrambled sequence does
not lead to the specific degradation of any cellular mRNA. Annexin V and
actin expression was assessed by Western blotting, after 12% gel
electrophoresis, using anti-annexin V (sc-1929) and anti-nonmuscle-F-actin
(cytoskeleton, 1/1000 and 1/200, respectively, both from Santa Cruz Bio-
technology), in the same protein extracts, at different periods of time after
annexin V-silencing siRNA transfection. Densitometric analysis of the films
was performed using a Biovision 1000 apparatus (Fischer Bioblock). Cell
viability was assessed by the trypan blue exclusion test when siRNA was
used (not shown).
In A549 cells stably expressing CFTR, annexin V overexpression was
performed. The annexin V cDNAwas amplified by PCR using complete cDNA
from HeLa cells as the template. The primers used were sense 5′-ACCTGAG
TAGTCGCCATGGCA-3′ and anti-sense 5′-CCCCGTGACACGGT-
CATCTTC-3′. Reactions were carried out with the following parameters:
denaturation at 94 °C for 15 min, annealing at 62 °C for 30 min, and extension at
68 °C for 1.5min, for a total of 30 cycles. After gel electrophoresis, PCR products
were purified with Qiaex II (Qiagen, Germany) and cloned into pcDNA3.1/His
(TOPO TA Expression Kit, Invitrogen, USA) according to the manufacturer's
instruction. Double-strand sequencing (ABI 310, Applied Biosystems, USA)
were performed on recombinant clones to ascertain that PCR amplification did
not introduce mistakes and the coding sequences were in frame. Annexin V
overexpression in cells was assessed by Western blotting as described above at
different post-transfection times.
2.3. Protein purification and overlay assay
The cDNA encoding NBD1 (nucleotides 420 to 650) was amplified by PCR
using the human CFTR cDNA as template and cloned into a baculovirus vector
encoding a C-terminal HisX6 tail (plasmid PVL1393, BD Biosciences). The
cDNA encoding the NBD1 domain was 33 amino acid residues longer than the
previously described human NBD1 domain, which was 453 to 650 [23]. The
NBD1 peptide was produced in Sf9 insect cells (BaculoGold expression system,
BD Biosciences) which were lysed in lysis buffer (50 mM Tris–HCl, 100 mM
NaCl, 1% Triton X-100 or 4% sodium pentadecafluorooctanoate (PFO, [24]),
1.1 μM leupeptin, 0.7 μM aprotinin, 120 μM PMSF, 1 μM iodoacetamide,
0.7 μMpepstatin and 1mMDIFP; all from Sigma). Homogenates were subjected
to 100,000×g centrifugation and NBD1-His was purified on an Ni-NTA column
(Qiagen) as previously described [25]. Elution was performed with imidazole-
containing buffer (pH 6.8), which has been shown to be the most efficient for this
purpose [26].
Using the same methodology as for NBD1, the full-length CFTR and the
delF508-CFTR protein were purified from the stably transfected A549 cells.
Pure annexin V protein was from Sigma.
Before overlay assay, CFTR, NBD1 and annexin V were subjected to SDS/
PAGE. In order to assess the purity of the proteins, the gels were stained with
NiAg. The purity of the CFTR, NBD1 and annexin V was further assessed by
Western blotting. The antibodies for CFTR and NBD1 detection were MM13-4
(1/1000, RD) and L12B4 (1/1000, Neo Markers), respectively.
Fig. 1. Detection of annexin V in CFTR co-immunoprecipitated complexes from
normal human tissues. (A) Magnetic beads were coated with the anti-CFTR
antibodies and incubated with protein extracts from normal human tissues
(upper airways). Complexes were subjected to SDS/PAGE (7.5%) and
transferred onto a membrane which was incubated with anti-CFTR antibodies.
CFTR is detected (170 kDa) whereas it is not present when the beads were
incubated with cells not expressing CFTR (A549). (B) Example of co-
immunoprecipitations performed in the presence of calcium (CaCl2, 10
−5 M), in
the presence of EGTA (10−3 M) and in the presence of EDTA (10−3 M).
Samples were resolved by a 12% gel electrophoresis and annexin V (35 kDa)
was detected by Western blotting. The observed signal representing the amount
of annexin V in the immunoprecipitated complexes is more intense in the
presence of calcium than in the presence of EDTA or EGTA. Therefore, annexin
V and CFTR are present in the same complex and the interaction is calcium-
dependent. No signal is observed in the negative control performed with proteins
extracted from A549 cells not transfected with the cDNA encoding CFTR.
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polyacrylamide gel) and transferred to a PVDF membrane (Amersham, France),
which was incubated with either purified NBD1 (10 μg/ml) or CFTR (10 μg/ml)
in TBS buffer (20 mM Tris–HCl, 0.5 M NaCl, 0.05% Tween 20, pH 7.5) in the
presence of 10−5 M CaCl2 or 10
−3 M EDTA, as previously described [27]. The
membranes were then incubated with the anti-CFTR or the anti-NBD1 mono-
clonal antibody and the blots were developed after incubation with secondary
antibodies using the ECLplus kit (Amersham). Control incubations omitting
CFTR, omitting NBD1 or omitting the primary or secondary antibodies were
performed. The specificity of the interaction was checked by using BSA as an
irrelevant protein instead of annexin V.
2.4. Surface plasmon resonance
Surface plasmon resonance (SPR) experiments were performed using a
BiacoreX apparatus. To test the interaction between annexinVand the full-length
CFTR protein and between annexin V and the NBD1 domain, histidine-tagged
CFTR or NBD1 proteins were immobilized by nickel chelation onto a NTA
sensor chip, according to the manufacturer's instructions (Biacore). The NTA
sensor chip, on which nitrilotriacetic acid is covalently linked to a carboxy-
methylated dextran matrix, was activated by a pulse of NiCl2 (500 μM), forming
a chelating complex with NTA, which binds the polyhistidine peptides. The
immobilization of the ligand (CFTR-His or NBD1-His) was adjusted to a low
level (2000 RU), such that mass transport limitation and rebinding of the analyte
to the immobilized ligand was minimal [28]. The injection of an anti-CFTR
antibody directed against the R-domain (MAB 1660, RD) and the injection of an
anti-NBD1 antibody (L12B4, Neo Markers) were used in order to control the
immobilized proteins (not shown). In a first set of experiments, different amounts
of annexin V (0.50, 0.75 and 1 μM) diluted in HBS-P (0.01 M HEPES, pH 7.4,
0.15 M NaCl, 0.005% surfactant P20, Biacore) were injected (20 μl/min) onto
CFTR. The involvement of MgATP (0.5, 1, 1.5 and 2 mM) and Ca2+ (100, 500
and 1000 nM using CaCl2) in the interaction between annexin Vand NBD1 was
studied. The binding of annexin V was evaluated 10, 30 and 100 s into the
dissociation phase. An irrelevant protein (BSA) was used as negative control. For
each experiment, the final curves were obtained by subtraction of the signal
corresponding to the empty flow cell, which was Ni charged (flow cell 1).
In the case of the NBD1-annexin V interaction, quantitative measurements
were performed in the absence and presence of physiological Ca2+ concentration
(500 nM) andMgATP. For each concentration of annexin V, steady-state binding
(Req) was measured and used to calculate the equilibrium constant KD. The
following equation was used, according to the BIA applications handbook
(Biacore):
Req=C ¼ KA  Rmax  KA  Req ð1Þ
where C is the annexin V concentration, Rmax is the total surface binding
capacity in RU and Req is the steady-state binding in RU obtained when the
equilibrium was reached for each concentration of annexin V. A plot of Req/C
against Req at different concentrations gave a Scatchard plot from which KD
was calculated.
SPR was also used to assess the specificity of the NBD1-annexin V
interaction. 8-cyclopentyl-1,3-dipropylxanthine (CPX, Sigma) which binds to
the wild-type and to the mutated NBD1 was injected on the immobilized wild-
type and on the delF508-CFTR proteins in order to saturate the NBD1 sites.
Annexin V was further injected to assess the inhibition of the interaction when
the NBD1 sites were blocked. To assess whether the annexin V binding to
NBD1 might be impeded by the delFF508 mutation, the mutated protein was
immobilized and annexin V was injected. Negative controls were performed
using an irrelevant protein (BSA) instead of CPX or instead of annexin V (not
shown). Each SPR experiment was performed at least three times.
2.5. SPQ fluorescence assay
Several cell lines were used in the 6-methoxy-N-(3-sulphopropyl) quino-
linium (SPQ) experiments: (1) A549 cells, (2) A549 cells stably expressing
CFTR, (3) A549 cells transfected with both the CFTR and the annexin V
cDNAs, and (4) A549 cells transfected with both the CFTR cDNA and the
siRNA directed against annexin V, in 6-well plates. Fluorescence assays wereperformed as previously described [29] using forskolin as a CFTR activator.
Cells were loaded with 10 mM SPQ and placed in a quenching NaI buffer. The
baseline fluorescence was measured in isotonic NaI buffer and cells were then
perfused with isotonic dequench buffer (NaNO3 replaced NaI). The perfusate
was then switched to dequench buffer plus agonist and requenched at the end of
the experiments. Each SPQ assay was performed at least five times with
different cell cultures. During the SPQ experiments the cell morphology and the
cell number per microscopic field were checked in order to ensure that there was
no difference between the cells in the presence or absence of siRNA.
SPQ experiments were also performed when annexin V was overexpressed in
cells that were transfected or not with the cDNA encoding CFTR. The methodology
was the same as described above. The controlswere performed using cells expressing
or not expressing CFTR which were transfected with the empty pcDNA3.1 vector.
2.6. In vitro phosphorylation of CFTR by PKA
Phosphorylation of the purified wild-type CFTR was carried out over the
range 0–800 Units/ml PKA (cAMP-dependent protein kinase, catalytic subunit,
Promega, France) using a luminescent kinase assay (Kinase-Glo-Plus Lumines-
cent Kinase Assay, Promega). This luminescent assay provides a homogeneous
method of determining any kinase activity based on the quantitation of ATP. The
generated luminescent signal is proportional to the amount of ATP present in the
reaction and inversely correlated with the amount of kinase activity. Experiments
were performed in multiwell plates, in triplicate, using a previously described
phosphorylation buffer (140 mM NaCl, 4 mM KCl, 2 mMMgCl2, 10 mM Tris–
HCl, 20 μMMgATP), in the presence of 0.5 mM CaCl2 or 1 mM EDTA [30], at
room temperature. When purified CFTR was used, it was diluted in
phosphorylation buffer in order to remove detergent as previously described
[30]. Results obtained with CFTR and CFTR combined with annexin V (5 μg of
each protein per well), in the presence of CaCl2 or EDTA were compared with
those using buffer alone (negative control). Experiments were also performed
using the immunoprecipitated CFTR, in the presence of 0.5 mM CaCl2 or 1 mM
EDTA and the results were compared with that of buffer alone. The linearity of
the luminescent response was tested during each experiment using 5 and 10 μg
Kemptide according to the manufacturer's instructions (Promega, France).
Kemptide, which is a specific peptide substrate for cAMP-dependent PKA, was
used as a positive control. Experiments were performed three times and the
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2.7. Immunofluorescence and confocal microscopy
For immunofluorescence studies, stably transfected A549 cells expressing
human CFTRwere grown on coverslips. Cells were fixed (4% paraformaldehyde
in phosphate buffer saline, overnight at 4 °C), permeabilized in PBS containing
0.25% saponin solution (30 min at room temperature (RT)) and blocked in the
presence of 1% BSA. Cells were further incubated with monoclonal anti-CFTR
antibodies (monoclonal, 1/100, MM13-4, RD) for 3 h at room temperature. After
successive washes in PBS, the cells were incubated with a secondary FITC-
labelled anti-mouse antibody (1/100, Sigma). Controls in which first or
secondary antibodies were omitted were performed. For siRNA experiments,
immunofluorescence was performed 40 h after transfection. Untransfected cells
were used as a negative control. To label the actin cytoskeleton, the cells were
incubated with phalloidin-FluoProbes®547 (1/40, Molecular Probes) according
to the manufacturer's instructions.
Confocal microscopy was performed on 7 μm thick cryosections of normal
human bronchi obtained from the Hôpital de la Cavale Blanche (Brest, France)
following approval by the local ethics committee. Sections were incubated with
monoclonal anti-CFTR (1/10; anti-C terminus MAB 25031, RD Systems) and
polyclonal anti-annexin Vantibodies (1/10; sc-1929, Santa Cruz Biotechnology)
for 3 h at room temperature. Sections were further incubated with FITC-labelled
anti-mouse or TRITC-labelled anti-goat secondary antibodies (Interchim) and
were observed using a confocal microscope (Zeiss). Negative controls, where
primary, secondary or both antibodies were omitted, were performed.Fig. 2. Direct interaction between annexin Vand the NBD1 of CFTR. (A, left panels) P
by gel electrophoresis (7%, 12% and 12%, respectively) of 2 μg of proteins and NiA
panels) showed that all the proteins were pure. (B) In overlay experiments, 3 μg
membrane which was incubated with either purified CFTR or purified NBD1. Using s
the molecular weight of annexin V, showed a direct interaction between annexin Vand
irrelevant protein (BSA). The corresponding Coomassie blue staining of the membr2.8. Cell surface expression of CFTR by biotinylation
To estimate the presence of the CFTR protein in the plasmamembranes of the
cells after the altered or increased annexin V expression, the proteins of the cell
surface were biotinylated. Four T75 cm2 flasks of 90–95% confluent cells were
washed three times with ice-cold PBS (pH 8.0) to remove any contaminating
proteins. The cells were incubated in Sulfo-NHS-SS-Biotin solution (Pin-
point™ Cell Surface Protein Isolation Kit, Pierce, USA) for 30 min at 4 °C,
scraped and centrifuged 3 min at 500×g. The pellet was suspended in lysis buffer
(Tris–HCl pH 6.8 50 mM; NaCl 100 mM; Triton X-100 2% and antiprotease
cocktail) and incubated for 30 min on ice. The cell lysates were clarified by
centrifugation (10,000×g for 2 min at 4 °C) and biotinylated proteins were
isolated on Immobilized NeutrAvidinTM Gel (Pierce, USA). In control ex-
periments we used A549 cells, which did not express the CFTR protein, and cells
transfected with both the cDNA encoding CFTR and the siRNA or with both the
cDNA encodingCFTR and annexinV. TheCFTR proteinwas further detected by
Western blotting as described above.
2.9. Relative quantification of annexin V transcripts
Total RNA was extracted using the RNeasy® Mini Kit (Qiagen). Its
concentration and quality were assessed using an Agilent 2100 Bioanalyzer
(Agilent) according to the manufacturer's instructions. Relative quantifications
of annexin V transcripts were assessed in a one-step format (100 ng total RNA)
using the QuantiTect® SYBR® Green RT-PCR Kit (Qiagen) with the ABI
PRISM® 7700 sequence detection system. Annexin V-specific primers and
amplification of annexin V were previously described [31]. The relative amountsurity of CFTR (170 kDa), NBD1 (25 kDa) and annexin V (35 kDa) was assessed
g staining. A single band was observed for each protein. Western blotting (right
of pure annexin V was subjected to SDS/PAGE (12%) and transferred onto a
pecific antibodies, the detection of CFTR and NBD1 at 35 kDa, corresponding to
both CFTR and NBD1. The specificity of this interaction was observed using an
ane shows the amounts of the loaded proteins.
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transfected with annexin V-silencing siRNAs and cells transfected with non-
silencing siRNAs (negative control siRNA). Each experiment was performed
three times (not shown).3. Results
3.1. CFTR–annexin V interaction is Ca2+- and ATP-dependent
To investigate the presence of both annexin V and CFTR in
the same protein complex, we performed co-immunoprecipita-
tion experiments using normal human tissues from the upper
airways. In Fig. 1A, we show that CFTR was present in the
immunoprecipitated complex, which was further used to
investigate the presence of annexin V. A control experiment
performed with proteins from cells which do not express the
CFTR protein was negative (Fig. 1A), showing the specificity of
this interaction. Another control experiment in which an
irrelevant antibody directed against mouse Ig was linked to the
beads was negative (not shown). Since calcium is involved in the
properties of annexin V [32,33,22,26], co-immunoprecipitation
was performed in the presence of Ca2+ ions, EGTA or EDTA,
using previously described concentrations [27]. We found that
more annexin V bound to CFTR in the presence of Ca2+ than in
the presence of EDTA or EGTA, when equal amounts of co-
immunoprecipitated complexes were loaded on a gel (Fig. 1B).
No signal was observed in the negative control performed with
cells which did not express the CFTR protein.
For overlay assays, the purity of the purified CFTR, NBD1
and of the commercially available annexin V protein was
assessed by gel electrophoresis followed by NiAg staining,
which is more sensitive than Coomassie blue staining and
permitted purity assessment because a single bandwas seen (Fig.
2A, left panels). Their molecular weights were as expected.
Protein purity was further assessed by Western blottings in
which a single band was seen for each protein (Fig. 2A, right
panels). The sharp band observed for the CFTR protein was
likely due to the fact that it was purified and because the amount
of loaded protein was lower than in usual Western blots.
In overlay assays, pure annexin V was subjected to SDS/
PAGE and transferred to a PVDF membrane, which was
incubated with either purified CFTR or NBD1. As shown in Fig.
2B, there was a direct interaction between annexin V and both
CFTR and NBD1. An irrelevant protein (BSA) was used and
ruled out non-specific interactions (Fig. 2B). As a conclusion,
these results demonstrated a direct interaction between CFTR
and annexin V, and between annexin Vand the NBD1 domain of
CFTR.
In SPR experiments, one protein is linked to a sensor chip
while the other protein is injected over the linked protein. The
interaction is observed using computerized analysis, as a curve
(sensorgram) showing association, equilibrium and dissociation
phases given as resonance units (RU) as a function of time (s).
We first immobilized CFTR-His proteins on the NTA sensor
chip and injected annexin V. We found that the RU values
increased with the amount of injected annexin V (Fig. 3A). The
specificity of the binding was checked by injection of anirrelevant protein (BSA), which did not induce a signal (not
shown). In further experiments, annexin V was injected on
immobilized NBD1-His proteins. Ten seconds into the dissoci-
ation phase, the RU values obtained with NBD1were 7.50, 9.46,
21.28 and 35.54 for 0.25, 0.50, 0.75 and 1 μM of annexin V,
respectively (Fig. 3B). These data confirm that annexin V binds
the NBD1 domain of the CFTR protein and are in accordance
with the results obtained in the overlay assays.
We also studied the influence of Ca2+ on the NBD1-annexin
V interaction. Considering that intracellular Ca2+ concentrations
are 100 nM, but may peak at 1 μM, three different concen-
trations (100, 500 and 1000 nM) were used to study the
interaction between NBD1 and annexin V. A calcium depen-
dence was observed (Fig. 3C). As intracellular calcium is taken
to be 500 nM, we used this single Ca2+ concentration to study
the interaction in the presence of both Ca2+ and MgATP. As
NBD1 binds ATP [30], the interaction between annexin V and
NBD1 was studied in the presence of increasing amounts of
MgATP. With 1 μM annexin V, the response reached a plateau
above 1 mM MgATP (data not shown). Therefore this con-
centration was used subsequently. As shown in Fig. 3D, the
presence of both Ca2+ (500 nM) and MgATP (1 mM) increased
the apparent affinity of 1 μM annexin V for NBD1. The plotted
curves (Fig. 3D) indicated that the bound annexin V peaked
with both MgATP and Ca2+ (418.7 RU after 10 s), whereas this
level was lower in the presence of Ca2+ alone (245.1 RU). At
the same time-point, the levels obtained with annexin Valone or
in the presence of MgATP were not significantly different (21.7
and 18.7 RU, respectively). A negative control was performed
by injecting BSA over NBD1. EDTA and EGTA could not be
used in the running buffer because they are known to inhibit
nickel chelation which was used to link NBD1 to the sensor
chip.
SPR analysis was performed as described in the Methods to
determine the equilibrium dissociation constant (KD) of NBD1
and annexin V in the absence and presence of both calcium and
MgATP. Increasing concentrations of annexin V were injected
over NBD1 and the resulting RU values were plotted against
annexin V concentration (Fig. 3E). As shown in the insets in
Fig. 3E, Scatchard analysis linearized the data from the satu-
ration binding experiments. The KD values were 4.3 nM and
1.6 nM in the absence and presence of both calcium and ATP,
respectively, indicating that the dissociation was reduced in the
presence of both calcium and ATP.
3.2. The interaction between annexin V and CFTR is at NDB1
A competition experiment showing that blocking the NBD1
binding site of annexin V with the competitive CPX was per-
formed using SPR. CPX was injected on the immobilized CFTR
protein to block all the NBD1 sites and annexin V was injected.
As shown in Fig. 4A, CPX inhibited the annexin V–CFTR
interaction. We concluded that NBD1 was the single annexin V
binding site in CFTR. The interaction between annexin Vand the
delF508-CFTR protein was also studied. As shown in Fig. 4B,
the mutation did not alter the annexin V interaction. Using the
delF508-CFTR protein, the SPR experiment with CPX was
Fig. 3. Study of the direct interaction between annexin Vand CFTR and study of the positive role of calcium and ATP by SPR. (A) Example of sensorgram obtained when
different amounts of annexin V were injected over the immobilized CFTR protein. (B) Example of sensorgram obtained when annexin V (0.25, 0.50, 0.75 and 1 μM) was
injected over the immobilized NBD1. (C) Effect of Ca2+ on annexin V (1 μM)–NBD1 binding. The figure shows an example of a sensorgram obtained in the presence of
100, 500 and 1000 nM Ca2+, showing the calcium dependence of the interaction. (D) Example of sensorgram obtained when 1 μM annexin V was injected on the
immobilizedNBD1, in the presence of 1mMATPor 500nMCa2+ or bothATPandCa2+. The highest level of bound annexinVwas obtained in the presence of bothATPand
Ca2+. (E) Determination of the dissociation constant of NBD1–annexin V binding in the absence and presence of 500 nM Ca2+ and 1 mMMgATP. Plots of the equilibrium
response (Req in RU) versus annexin V concentration were determined when the injection curve showed a plateau. Insets: Scatchard analysis linearizing the data from the
saturation binding experiments, to determine KDs. The R
2 values for the linear fit are indicated. BSAwas used as a negative control in each experiment.
1126 P. Trouvé et al. / Biochimica et Biophysica Acta 1772 (2007) 1121–1133
Fig. 4. Inhibition experiment using SPR. (A) Example of sensorgram obtained
when CPX was injected on the immobilized CFTR to block NBD1 followed by
the injection of 1 μM annexin V, in the presence of 1 mMATP and 500 nMCa2+.
The last injection of CPX shows that all the NBD1 sites were blocked because
the response is not increased. The injection of annexin V gave no response
indicating that CPX inhibited the interaction with CFTR. (B) Example of
sensorgram obtained when annexin V (0.25, 0.50, 0.75 and 1 μM) was injected
over the immobilized delF508-CFTR in the presence of 1 mM ATP and 500 nM
Ca2+. The response is comparable to that obtained with the wild type CFTR
indicating a direct annexin V–delF508-CFTR interaction. (C) The same
experiment as in (A) was performed using the delF508-CFTR protein. The
injection of annexin V gave no response indicating that CPX inhibited the
interaction with delF508-CFTR.
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delF508 CFTR protein interaction (Fig. 4C). From these ex-
periments we concluded that NBD1 is the single annexin V
binding site in the wild-type CFTR and in the delF508-CFTR
protein. Furthermore, the delF508 mutation did not alter the
annexin V–CFTR interaction.
3.3. Annexin V–CFTR interaction is necessary for normal
CFTR channel function
The physiological relevance of the interaction was studied.
Since annexin V and CFTR interact, we hypothesized that this
interaction has functional implications and that a reduced
amount of annexin V in cells could modify CFTR function.
Using macroscopic Cl− flux through the CFTR channel, and
SPQ fluorescent indicator, we first noticed that the expressed
CFTR was functional in our cells, whereas no Cl− flux was
observed in untransfected cells. This was in accordance with the
immunofluorescence and Western blottings performed tovalidate the cell model. We compared the results obtained with
A549 cells, A549 cells stably expressing CFTR, and A549 cells
stably expressing CFTR in which annexin V expression was
inhibited by siRNA transfection. Western blotting 0, 24, 40 and
72 h after transfection with siRNA directed against annexin V
indicated that its protein level was minimal at 40 h (Fig. 5A). At
this time-point, relative quantification of the annexin V mRNA
showed it was reduced by 69% (±10%, data not shown). As
annexin V is an actin-binding protein, the use of siRNA directed
against annexin V could alter actin accumulation which could
lead to modified chloride channel function of CFTR protein.
Therefore, the level of actin protein was checked by Western
blot. As shown in Fig. 5A, actin expression was not modified
during the same time-course, indicating the specificity of the
siRNA. The use of an irrelevant scrambled siRNA did not
modify the amounts of either annexin V or actin, further in-
dicating a specific effect of the siRNA. As shown in Fig. 5B,
SPQ experiments indicated that inhibition of annexin V reduced
Cl− efflux via CFTR. The correlation between annexin V down-
expression and CFTR activity was studied 24, 40 and 72 h after
siRNA transfection. The drop (between 0 and 40 h after siRNA
transfection) and then the increase (at 72 h after transfection) in
annexin V expression (Fig. 5A) was associated with a drop and
then an increase in CFTR chloride channel function (Fig. 5C).
Nevertheless, the chloride flux did not reach its initial values at
72 h after transfection, perhaps because the molecular machinery
needed to be active for longer. Controls with the siRNA buffer
alone or with the scrambled siRNA did not impair the CFTR
chloride channel function (Fig. 5C).We concluded that annexin V
is necessary for normal CFTR channel function and that the effect
of reducing the annexin V level was specific. During the SPQ
experiments, the cell number in each microscopic field and the
cell morphology were assessed. Because they were identical to
those of cells not transfected with siRNA, we also concluded that
cell viability was not modified in the presence of siRNA. Cell
viability was further assessed using trypan blue (not shown).
The effect of annexin V overexpression on the chloride
channel function of CFTR was also studied. Annexin V
expression was assessed at increasing time-points after the
transfection (not shown). As shown in Fig 6A, the expression
was increased 24 h after the transfection (69.8±0.8%),
compared with controls. Actin expression was not modified at
this time-point. The involvement of annexin V overexpression
on the chloride channel function of CFTR was assessed by SPQ
and was compared with that of cells which transfected with the
empty vector. As shown in Fig. 6B, CFTR function was
increased when annexin V expression was increased.
Therefore, the down-regulation of annexin V reduced CFTR
function, which increased when annexin V was overexpressed.
3.4. Cell morphology, actin and CFTR localization when
annexin V expression is modulated
As annexin V is an actin-binding protein, and because actin is
necessary for normal CFTR function, cell morphology as well as
actin and CFTR distribution were studied by co-immunofluo-
rescence in A549 cells 40 h after transfection with siRNA
Fig. 5. Annexin V is necessary for CFTR chloride channel activity. (A) Western blot showing the expression of annexin V (upper panel) and actin (lower panel) in the
presence of siRNA directed against GFP and 0, 24, 40 and 72 h after transfection of the siRNA directed against annexin V. Twenty μg of total protein were loaded on
the gel. Annexin Vand actin were detected on the same membrane. Pure annexin V was used as a control (1 μg). The Coomassie blue staining of the membrane (right
panel) indicates that the amount of loaded protein is the same in all lanes. Histograms represent the relative quantitation of annexin Vand actin. The actin level was not
modified, whereas the level of annexin V was minimal 40 h after siRNA transfection. (B) Macroscopic Cl− flux experiments. The curves from the SPQ experiments
reflect the activity of CFTR as a chloride channel on forskolin activation. The upper curve (black circles) was obtained with stably transfected A549 cells expressing
CFTR (n=7). The middle curve (white triangles) was obtained with untransfected cells (n=12). Finally, the lower curve (white circles) reflects the activity of the CFTR
protein in the presence of siRNA against annexin V (n=6) which abolished Cl− flux (pb0.001) giving results similar to those of cells without CFTR. A cAMP-
stimulating mixture of IBMX (100 μM) and forskolin (10 μM) was added at the indicated time. F/F0 is the normalized fluorescence and bars represent SEM. (C) Time
dependence between CFTR activity and siRNA post-transfection time. Chloride flux was measured without siRNA transfection (white circles) and 24 (white
triangles), 40 (black lozenges) and 72 h (white squares) after siRNA transfection. The chloride flux was minimal when the expression of annexin V was decreased. The
transfection buffer alone or the scrambled siRNA had no effect upon chloride flux (not shown). Bars represent standard deviations (SDs) from at least five experiments.
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in cellular morphology, actin distribution or actin content by
comparison with a control without siRNA (Fig. 7). CFTRdistribution was modified by the presence of siRNA directed
against annexin V. As shown in Fig. 7, CFTR protein was mainly
detected in membranes in the absence of the siRNA directed
Fig. 6. Effect of the overexpression of annexin V upon the chloride channel function of CFTR. (A) Example of Western blot showing the expression of annexin V
(upper panel) and actin (lower panel) when the cells are transfected with the empty pcDNA3.1 vector or with the vector in which the cDNA encoding annexin V is
inserted (24 h post-transfection, upper panel). In the presence of the cDNA, annexin V is overexpressed in the cells, whereas the actin level is not modified (lower
panel). Ten μg of total protein were loaded on the gel. (B) Macroscopic Cl− flux experiments. The curves from the SPQ experiments were recorded as described above.
The upper curves were obtained with stably transfected A549 cells expressing CFTR in the presence of the empty pcDNA3.1 vector (white squares) and in the presence
of the vector in which the cDNA encoding annexin V was ligated (black squares). The lower curves were obtained with untransfected cells in the presence of the empty
pcDNA3.1 vector (white circles) and in the presence of the vector in which the cDNA encoding annexin V was ligated (black circles). The chloride channel activity of
CFTR was increased when annexin V was overexpressed. F/F0 is the normalized fluorescence and bars represent SEM (n=4).
1129P. Trouvé et al. / Biochimica et Biophysica Acta 1772 (2007) 1121–1133against annexin V. In cells transfected with siRNA, CFTR
labelling was diffuse and the membranes were not labelled
anymore.We concluded that decreased annexin Vexpression led
to reduced membrane localization of CFTR protein.
CFTR localization was further studied in biochemical assays.
The membrane proteins were labelled and purified in order to
assess the presence of CFTR protein. As shown in Fig. 8A,
CFTR was not present in the cellular membranes in cells that
were not transfected with the cDNA encoding CFTR. In CFTR-
expressing cells, decreased annexin Vexpression induced a loss
of membrane localization of CFTR, whereas it was observed
when a scrambled siRNA was used. The same experiment was
performedwhen annexin Vwas overexpressed, and an increased
localization of the CFTR protein within the membranes was
observed (Fig. 8B). The decreased annexin V expression in-
duced a total loss of CFTR in the membranes, suggesting the
importance of annexin V in integration of CFTR within mem-
branes. This result was in accordance with the immunofluores-
cent study (Fig. 7).
3.5. CFTR and annexin V distribution in human bronchial tissues
We found that annexin V could bind the CFTR protein.
Therefore, we investigated the co-distribution of both proteins
within cells in normal human tissues. Double staining of CFTRand annexin V was performed in normal human bronchi
(Fig. 9A). In confocal experiments, CFTR was mainly observed
in the membranes of epithelial cells from normal bronchi, with a
stronger signal in apical membranes (Fig. 9A, left panel). In a
study using CFTR antibodies, we previously observed this
apical labelling [34]. Some annexin V labelling was seen in the
cytosol close to the apical membrane (Fig. 9A, middle panel).
To our knowledge, this is the first time that annexin V lo-
calization has been described in human bronchial cells. In
Fig. 9A (right panel), the merged images indicate that both
proteins are partially distributed close to the apical region of
normal human bronchial cells with interacting regions. Because
CFTR is integrated inside the apical membranes and because
annexin V was observed under the membranes since it is not an
integrated protein, the co-distribution was partial. This was
further assessed in an experiment performed with another tissue
when a region where annexin V and CFTR were co-distributed
was observed at high magnification (Fig. 9B).
4. Discussion
Based on the properties of both annexin Vand CFTR, and on
the fact that annexin V is overexpressed in CF epithelial cells, we
investigated the role of annexin V in CFTR-expressing cells. We
hypothesized that annexin Vmay be involved in CFTR function.
Fig. 7. Cell morphology and CFTR distribution following annexin V silencing.
Immunostaining of CFTR and actin (phalloidin) was performed in the absence
or presence of siRNA (40 h). Two examples are shown. In the absence of the
siRNA, the CFTR was seen in the membranes of the cells (white arrows, upper
panel). In the presence of the siRNA, the CFTR labelling was diffuse and was
not seen in the membrane (middle panel). In the right panel, the nuclei were
stained with DAPI. Actin (red, lower panel) distributions did not differ between
the two conditions, showing that the siRNA had no effect on cell morphology.
Fig. 8. CFTR protein detection at the cell surface of A549 cells when annexin V
expression is modulated. Membrane proteins were biotinylated and CFTR was
detected by Western blotting (7.5% gel electrophoresis). (A) Whereas the CFTR
protein is observed in the cell membrane of CFTR-expressing cells in the
presence of the scrambled siRNA, it is not seen when cells are transfected with
the siRNA directed against annexin V. Untransfected cells, which did not
express CFTR, were used as negative control. The reduced annexin Vexpression
induced a loss of CFTR in the membranes. (B) CFTR is detected in the
membrane of the cells that were transfected with both the cDNA encoding
CFTR and the empty pcDNA3.1 vector. In CFTR-expressing cells, the CFTR
was increased in the presence of the pcDNA3.1 vector in which the annexin V
cDNAwas ligated. Untransfected cells, which did not express CFTR, were used
as negative control. Therefore, annexin V overexpression induces increased
CFTR localization in the membranes.
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involvement of annexin I in CF [35] by the interaction between
annexinVwithmembrane protein andwith some exchanger [21]
and by the modulated expression of annexin V in CF [16].
Co-immunoprecipitation using normal human tissues
showed that annexin V and CFTR are present in the same
protein complex. This led us to investigate whether the inter-
action is direct and to determine which CFTR domain is
involved. Because NBD1 and annexin V may interact with PS
[17,19,20], we hypothesized that they could be co-distributed
and interact. Using purified NBD1, we showed a direct inter-
action between annexin V and NBD1 which is involved in
CFTR chloride channel function and in most of the CFTR
mutations. Further studies of the annexin V–NBD1 interaction
were performed using the previously described SPR technology
[36]. Because ATP binding is a feature of NBD1, and as an-
nexins are known to be involved in PLA2 inhibition, membrane
trafficking and exocytosis regulation, cytoskeletal protein
binding, transmembrane channel regulation and intracellular
signalling in a Ca2+-dependent manner [32,33,37], we studiedthe involvement of MgATP and Ca2+ in the formation of the
annexin V–CFTR complex. Our results indicate that the
association between annexin V and CFTR is Ca2+- and ATP-
dependent, and the calculated dissociation constants were in
accordance with our biochemical results. In the presence of Ca2+
and ATP, the interaction between NBD1 and annexin V was
characterized by a KD value of 1.6 nM. The interaction between
annexin Vand glycosaminoglycan was previously studied using
SPR [38] and the Ca+2 dependence of this binding afforded a
lower KD value than the one we observed. Therefore, we
confirm the importance of the Ca+2 dependence in annexin V
function and show that it may function mainly inside the cells.
This point is further reinforced by the previously described
interaction of annexin V with the sodium–calcium exchanger
and caveolin 3 [21], which indicate that annexin V may modu-
late ionic homeostasis in cells.
At this point our work was descriptive, and we then studied
the physiological implications of the interaction and showed
that annexin V is involved in normal CFTR Cl− channel func-
tion. Reduced annexin V expression lowered chloride channel
activity of the CFTR protein, whereas annexin Voverexpression
led to an increased chloride flux. This indicated that annexin V
is necessary for normal CFTR-mediated chloride channel
function. This result, together with the described annexin V
overexpression in CF patients, confirms the previous hypothesis
assessing that annexin V may compensate the CFTR defect in
CF [16].
Annexin V binds to actin [15,33], which is involved in
cAMP-dependent CFTR activation [39,40]. Since the cellular
actin organization and level are not altered in our cells, we
conclude that the decreased Cl− channel function is due to the
Fig. 9. Example of the distribution of CFTR and annexin V in normal human bronchi observed by confocal microscopy. (A) CFTR (FITC, green) is mainly observed in
apical membranes of epithelial cells (left panel). Some annexin V (TRITC, red) is apically localized, close to the membrane (middle panel). Merged images of CFTR
and annexin V show that both proteins are partially co-distributed in the apical membrane (yellow). First and second lines represent increasing magnifications. The
third line represents an increased magnification of the inset of the second line. (B) High magnification of a image of merged labelling of both CFTR and annexin V in
another human bronchi. Whereas CFTR is in the apical membrane of the cells, annexin V is seen under the membrane because it is not an integrated protein. The co-
distribution of both proteins (yellow) is indicated by arrows. L: Lumen of the bronchi.
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CFTR.
The mechanism by which annexin V expression could
modify CFTR function was studied and two hypotheses were
tested. First, we hypothesized that annexin V could be involved
in CFTR membrane localization and in phosphorylation of
CFTR. Therefore, we investigated the involvement of annexin
V in the targeting of CFTR to the cell membrane and showed
that the localization of CFTR was correlated with annexin V
expression. Immunofluorescence and biochemical studies indi-
cate that the presence of the CFTR protein in the membranes isdependent on the protein expression of annexin V. Our second
hypothesis was an involvement of annexin V in CFTR phos-
phorylation. However, siRNA directed against annexin V did
not alter CFTR phosphorylation (not shown). Furthermore, this
second hypothesis was ruled out because it was recently shown
that the depletion of endogenous annexin V with siRNA inhibits
delta-PKC translocation [41]. Also, annexin V inhibition of
PKC through sequestering of its substrate is largely documented
and the decreased annexin V expression in our experiments
could in turn lead to increased PKC activation, which would not
explain the decreased function of CFTR.
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cellular calcium, which may be modulated by annexin V. An-
nexin V is a calcium-binding protein which exhibits calcium
channel activity [33,42,43] and modulation of its expression
could modify intracellular calcium, which is known to modulate
CFTR chloride channel activity [44,45].
The relevance of our findings was investigated in vivo, using
co-immunoprecipitations in human tissues. Our confocal micro-
graphs showing partial co-distribution of annexin V and CFTR
in human normal bronchi are similar to those reported for
CFTR-associated protein 70 [46]. This partial co-distribution
can be explained because annexin V is mainly found under the
apical membranes and is not a membrane protein, and because
CFTR is a membrane-spanning protein.
The present results are of importance because the quaternary
structure of proteins is of crucial importance for both their
maturation and normal function [47]. It is therefore essential to
identify new CFTR partners that may be involved in the
genotype–phenotype relationship in CF.We focused on annexin
V because it has recently been shown to be one of the most
abundant proteins in CF cells [48], and have shown for the first
time its functional interaction with CFTR. Because the most
frequent CF-causing mutation is a deletion in NBD1 (delF508),
it can be hypothesized that the interaction between CFTR and
annexin V might be impeded, increasing the lethal effect of this
mutation. Nevertheless, our experiments indicate that the
interaction is not impeded by this mutation. According to the
present results, the previously described overexpression of
annexin V in CF can be seen as a cellular response, which tends
to compensate for the CFTR defect, as proposed by Della
Gaspera and co-workers [16].
Besides CF, we report new information regarding the
function of annexin V in cells. Our results showing a direct
interaction between annexin V and CFTR, taken together with
recent data showing an association between annexin A5 and
cardiac Na(+)/Ca(2+) exchanger and between annexin V and
caveolin [21], indicate that annexin V binds a membrane
protein. Because annexin V is likely to be secreted together
with lung lamellar body, which is thought to be an intra-
cellular store of pulmonary surfactant secreted by alveolar
type II cells [49], a complex involvement in CF may be
ascribed to annexin V.
Showing that annexin V is involved in the presence of the
CFTR protein in the cell membrane and that it is therefore
involved in the chloride flux via CFTR, the present work
provides evidence for a new CFTR partner with functional
implications and gives new information on the molecular
pathophysiology of CF. Furthermore, we show that annexin V
overexpression leads to increased chloride channel function
through CFTR. Therefore, annexin V may be seen as a new
potential therapeutic target in CF.
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